Where does Inflazome Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Inflazome Limited ranks #14,689 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Inflazome Limited hold?

Inflazome Limited holds 20 US utility patents granted between 2021 and 2025, spanning 7 technology areas.

What is Inflazome Limited's Innovation Score?

Inflazome Limited has an Innovation Score of 51.9 out of 100 (top 11% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Inflazome Limited focus on?

Inflazome Limited's top technology area is C07D (Heterocyclic Compounds) with 20 patents, ranking #448 of 3,165 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is Inflazome Limited's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Inflazome Limited.

What does claim depth mean for Inflazome Limited's patents?

Inflazome Limited's patents average 20.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Inflazome Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Inflazome Limited

USPTO PatentsView assignee record - 20 granted patents across 7 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Inflazome ranks #14,689 of 49,997 tracked US assignees by granted-patent volume, with 20 patents across 7 technology areas.

#14,689
of 49,997 US assignees by volume: Top 11%
by Innovation Score (51.9/100): 20.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R14689 · Foreign Corporation #14,689 · 20 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-SMALL 20 grants
MID-PACK #14,689/49,997
PHOTO-FINISH Imiracle (HK)
CPC-NARROW C07D · 7 areas
INNOV-PAR 51.9/100
CLAIMS-DENSE 20.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2021–2025 · 5y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Imiracle (HK) Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Inflazome’s 51.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.5 pts (20%) Velocity 20.0 pts (39%) Breadth 9.4 pts (18%) Claim depth 12.0 pts (23%)

Qualcomm Incorporated · highest

85
Inflazome · this assignee

52
3D Lighting… · lowest

7

What this shows Inflazome's Innovation Score is 51.9/100 (top 11% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Inflazome?

Each dot is one of Inflazome’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Inflazome’s own 20.0 claims/patent is ABOVE the 10.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Inflazome vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Inflazome's grants concentrate

Inflazome Limited is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2024 (7 grants) versus a trough of 1 in 2021. By volume, Inflazome sits between Imiracle (HK) Limited and Ipco 2012 Limited.

Inflazome's three-year grant acceleration

Inflazome Limited shows 17 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Imiracle (HK)

20
Inait

20
Incheon Universit…

20
Infectious Diseas…

20
Inpaq Technology

20
Interface Optoele…

20
Interman

20
Ipco 2012

20
Inflazome ◀

20

What this shows Inflazome holds 20 patents at rank #14,681, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Inflazome

By rank, the assignees closest to #14,681 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Inflazome's primary technology class.

Inflazome's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

52 Top 11% higher than 89% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2021–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.

View data table

Inflazome Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2021	1	5.0%
2022	4	20.0%
2023	6	30.0%
2024	7	35.0%
2025partial year	2	10.0%

Which technologies does Inflazome Limited patent most?

C07D - Heterocyclic Compounds 20

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 14

C07C - Acyclic OR Carbocyclic Compounds 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Inflazome Limited's patent record in context - here's where to go next.

Inflazome Limited's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #14,689 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Inflazome Limited against Imiracle (HK) Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 51.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.